Utility of Serum S100B Level, SFSR and OESIL Scores in Anticipating Short Term Adverse Events of Discharged Syncope Patients

2012 ◽  
Author(s):  
Haldun Akoglu ◽  
Arzu Denizbasi ◽  
Ozlem Guneysel ◽  
Ozge Ecmel Onur ◽  
Serkan Emre Eroglu ◽  
...  
Keyword(s):  
Adverse Events ◽  
S100b Level ◽  
Short Term ◽  
Serum S100b ◽  
Serum S100b Level

scholarly journals The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Asuman Celikbilek ◽  
Mehmet Celikbilek ◽  
Seda Sabah ◽  
Nermin Tanık ◽  
Elif Borekci ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Severity Index ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
S100b Level ◽  
Serum Samples ◽  
Serum S100b ◽  
Enteric Glial Cells ◽  
Serum S100b Level

Objective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC activation and disease activity in UC patients.Methods. This clinical prospective study included 35 patients with UC and 40 age- and sex-matched controls. The diagnosis of UC was based on standard clinical, radiological, endoscopic, and histological criteria. Clinical disease activity was evaluated using the Modified Truelove-Witts Severity Index. Serum samples were analyzed for human GFAP and S100B using commercial enzyme-linked immunosorbent assay kits.Results. GFAP was not detected in the serum of either UC patients or controls (P>0.05). However, we found a significant (P<0.001) decrease in the serum S100B levels in the UC patients. No correlation between the serum S100B level and the disease activity or duration was observed (P>0.05). The serum S100B levels did not differ between UC patients with active disease (24 patients, 68.6%) or in remission (11 patients, 31.4%) (P>0.05).Conclusions. Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients.

Serum S100B level may be correlated with carbon monoxide poisoning

2015 ◽  
Vol 27 (1) ◽  
pp. 69-75
Author(s):  
Hui Liu ◽  
Yu Zhang ◽  
Yan-Bo Ren ◽  
Jian Kang ◽  
Jing Xing ◽  
...  
Keyword(s):  
Carbon Monoxide ◽  
Carbon Monoxide Poisoning ◽  
S100b Level ◽  
Serum S100b ◽  
Serum S100b Level

Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20042-e20042
Author(s):  
Igor Samoylenko ◽  
Tatiana Zabotina ◽  
Irina N. Mikhaylova ◽  
George Z. Chkadua ◽  
Olga V. Korotkova ◽  
...  
Keyword(s):  
Dendritic Cell ◽  
Metastatic Melanoma ◽  
Stable Disease ◽  
Objective Response ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
S100b Level ◽  
Baseline Serum ◽  
Serum S100b ◽  
Serum S100b Level

e20042 Background: The purpose of this sub study was to identify peripheral blood biomarkers associated with the therapeutic effect of immunotherapy with dendritic cell vaccine in patients with metastatic melanoma (MM). Methods: Patients (pts) with low disease burden achieved disease control after two cycles of chemo (cisplatine, vinbalstie, DTIC) were randomized dendritic cell vaccine (DC) or three cycles of chemo. Vaccination schedule consisted of 5 subcutaneous injections of dendritic cell (DC) vaccine (2×106 cells pulsed with autologous lysate) with 14 days intervals. S100B level, LDH level, and peripheral blood lymphocytes immune phenotype were assessed before treatment, after two cycles of chemo and after each vaccination cycle. Results: 104 pts were included in the study, 30 pts were randomized to DC arm, 29 pts were randomized to continue chemo. In pts with rapid disease progression baseline serum S100b level was significantly higher compared to patients with objective response or stable disease (0.874±1.15 mcg/L vs. 0.361±0.66 mcg/L, P=0.002). Similar results were found for baseline serum LDH level (559.8±469.7 U/L vs. 412.5±184.4 U/L, P=0.005) and serum S100b level after 2 cycles of chemo (0.688±0.855 mcg/L vs. 0.187±0,29 mcg/L, P<0.001). Contrary, baseline CD3+HLA-DR+ and CD4+CD25+ lymphocytes levels after 2 cycles of chemo were significantly higher in pts with disease control (11.9±8.9% vs. 8.9±5.3%, P=0.047 and 14.4±8.3% vs. 11.3±5.5%, P=0.036 respectively).In pts randomized to DC arm following markers were associated with long lasting objective response or stable disease course (>6 months): lower baseline S100b level (0.133±0.120 mcg/L vs. 0.445±0.406 mcg/L, P=0.014), lower S100b level after 2 cycles of chemo (0.105±0.095 mcg/L vs. 0.255±0.154 mcg/L, P=0.048), higher proportion of active CD8+lymphocytes prior to vaccination (74.7±3.6% vs. 51.7±14.2%, P=0.05); and more prominent increase of NK-cells CD3-CD16+CD56+ from baseline (increase in 76.5%±41.12% vs. 4.5±28.8%, P=0.01). Conclusions: Biochemical and immunological markers may be helpful when selecting patients with metastatic melanoma for immunotherapy with dendritic cell vaccine.

Impact of operative time on short-term adverse events following total shoulder arthroplasty

2020 ◽  
Vol 30 (3) ◽  
pp. 227-236
Author(s):  
Kevin I. Kashanchi ◽  
Alireza K. Nazemi ◽  
David E. Komatsu ◽  
Edward D. Wang
Keyword(s):  
Adverse Events ◽  
Shoulder Arthroplasty ◽  
Operative Time ◽  
Total Shoulder Arthroplasty ◽  
Short Term

scholarly journals Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events?

2017 ◽  
Vol 18 (5) ◽  
pp. 963-971 ◽  
Author(s):  
Nicole Durfey ◽  
Brian Lehnhof ◽  
Andrew Bergeson ◽  
Shayla Durfey ◽  
Victoria Leytin ◽  
...  
Keyword(s):  
Adverse Events ◽  
Short Term ◽  
Severe Hyperkalemia

scholarly journals GCT-08. PROTON BEAM RADIOTHERAPY FOR PEDIATRIC AND YOUNG-ADULT PATIENTS WITH INTRACRANIAL GERM CELL TUMOR

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii329-iii329
Author(s):  
Minako Sugiyama ◽  
Takayuki Hashimoto ◽  
Takashi Mori ◽  
Kazuya Hara ◽  
Yukayo Terashita ◽  
...  
Keyword(s):  
Young Adult ◽  
Adverse Events ◽  
Germ Cell ◽  
Cell Count ◽  
Proton Beam ◽  
Adult Patients ◽  
Short Term ◽  
Intracranial Germ Cell Tumor ◽  
X Ray ◽  
Proton Beam Radiotherapy

Abstract BACKGROUND To reduce treatment-related adverse events in pediatric and young-adult patients with brain tumors, proton beam radiotherapy (PBT) has recently been performed instead of conventional X-ray radiotherapy. However, whether PBT is as effective as X-ray radiotherapy has not been sufficiently investigated, especially in patients receiving whole-ventricular irradiation. METHODS We report a retrospective observation of 15 patients with intracranial germ cell tumors (GCT), who received PBT at our institution from April 2014 to September 2019. We evaluated their clinical course, short-term adverse events, and prognosis. RESULTS/ CONCLUSION Fifteen patients (9 males and 6 females; median age 13 years) who received PBT following induction chemotherapy were analyzed. Nine patients received 23.4–27.0 GyE of whole-ventricular irradiation due to GCT in the pituitary gland, pineal body, or hypothalamic area. Three patients received 23.4 GyE of whole-brain irradiation: one of them had boost irradiation for basal ganglia. Three patients received 30.6 GyE of craniospinal irradiation (CSI). Six of the 15 patients experienced nausea (grade 2, according to the CTCAE version 4.0). Four patients, including two who received CSI, showed myelosuppression: decrease in white blood cell count, lymphocyte cell count, and neutrophil count (grade 3). No other severe short-term adverse events of &gt;grade 2 was observed in any of the patients. At a median follow-up of 21 months (2-62 months) after irradiation. all patients are alive without recurrence. Our results may be encouraging and further investigations with a larger scale is warranted.

Sign in / Sign up

Export Citation Format

Share Document